• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    9/14/22 1:33:47 PM ET
    $ALT
    $ATXI
    $AURA
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALT alert in real time by email

     

    Gainers

    • Avenue Therapeutics (NASDAQ:ATXI) stock rose 77.1% to $0.41 during Wednesday's regular session. Avenue Therapeutics's stock is trading at a volume of 56.8 million shares as of 13:30 EST. This is 18245.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $9.0 million.
    • bioAffinity Technologies (NASDAQ:BIAF) stock increased by 51.64% to $6.28. The current volume of 42.3 million shares is 800.8% of bioAffinity Technologies's average full-day volume over the last 100 days (last updated at 13:30 EST). The market value of their outstanding shares is at $17.1 million.
    • NeuroOne Medical Tech (NASDAQ:NMTC) shares moved upwards by 24.3% to $2.25. As of 13:30 EST, this security is trading at a volume of 679.2K shares, making up 372.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $36.4 million.
    • Tenax Therapeutics (NASDAQ:TENX) stock increased by 20.57% to $0.25. Tenax Therapeutics's stock is trading at a volume of 7.8 million shares as of 13:30 EST. This is 2911.4% of its average full-day volume over the last 100 days. The company's market cap stands at $6.3 million.
    • Rhythm Pharmaceuticals (NASDAQ:RYTM) stock increased by 20.2% to $29.81. Trading volume for Rhythm Pharmaceuticals's stock is 1.2 million as of 13:30 EST. This is 49.9% of its average full-day volume over the last 100 days. The company's market cap stands at $1.5 billion.
    • Fusion Pharmaceuticals (NASDAQ:FUSN) stock rose 19.89% to $3.52. Trading volume for Fusion Pharmaceuticals's stock is 125.8K as of 13:30 EST. This is 193.7% of its average full-day volume over the last 100 days. The company's market cap stands at $152.9 million.

    Losers

    • Comera Life Sciences (NASDAQ:CMRA) stock declined by 30.1% to $2.7 during Wednesday's regular session. As of 13:30 EST, Comera Life Sciences's stock is trading at a volume of 4.3 million, which is 89.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $51.5 million.
    • Altimmune (NASDAQ:ALT) shares fell 25.72% to $15.14. Trading volume for this security as of 13:30 EST is 42.1 million, which is 2399.7% of its average full-day volume over the last 100 days. The company's market cap stands at $742.2 million.
    • Caladrius Biosciences (NASDAQ:CLBS) shares decreased by 21.03% to $0.4. As of 13:30 EST, Caladrius Biosciences's stock is trading at a volume of 24.6 million, which is 17203.9% of its average full-day volume over the last 100 days. The company's market cap stands at $24.4 million.
    • Rubius Therapeutics (NASDAQ:RUBY) shares fell 15.86% to $0.78. As of 13:30 EST, Rubius Therapeutics's stock is trading at a volume of 2.0 million, which is 72.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $70.4 million.
    • BioLine Rx (NASDAQ:BLRX) shares declined by 14.89% to $1.43. As of 13:30 EST, this security is trading at a volume of 150.4K shares, making up 113.4% of its average full-day volume over the last 100 days. The company's market cap stands at $68.4 million.
    • Aura Biosciences (NASDAQ:AURA) shares declined by 12.51% to $13.57. The market value of their outstanding shares is at $397.2 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALT
    $ATXI
    $AURA
    $BLRX

    CompanyDatePrice TargetRatingAnalyst
    Altimmune Inc.
    $ALT
    3/18/2026$12.00Buy
    Truist
    Tenax Therapeutics Inc.
    $TENX
    3/17/2026$35.00Overweight
    Cantor Fitzgerald
    Rhythm Pharmaceuticals Inc.
    $RYTM
    2/19/2026$478.00Outperform
    RBC Capital Mkts
    Altimmune Inc.
    $ALT
    1/28/2026$20.00Overweight
    Barclays
    Aura Biosciences Inc.
    $AURA
    11/26/2025$13.00Outperform
    Evercore ISI
    Rhythm Pharmaceuticals Inc.
    $RYTM
    11/25/2025$136.00Buy
    Citigroup
    Rhythm Pharmaceuticals Inc.
    $RYTM
    11/5/2025Outperform → Perform
    Oppenheimer
    Tenax Therapeutics Inc.
    $TENX
    9/8/2025$20.00Overweight
    Piper Sandler
    More analyst ratings

    $ALT
    $ATXI
    $AURA
    $BLRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Altimmune with a new price target

    Truist initiated coverage of Altimmune with a rating of Buy and set a new price target of $12.00

    3/18/26 4:00:13 PM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Tenax Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $35.00

    3/17/26 8:15:05 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Rhythm Pharmaceuticals with a new price target

    RBC Capital Mkts initiated coverage of Rhythm Pharmaceuticals with a rating of Outperform and set a new price target of $478.00

    2/19/26 7:52:12 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    $ATXI
    $AURA
    $BLRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Serlin Philip A

    3 - BioLineRx Ltd. (0001498403) (Issuer)

    3/27/26 4:05:45 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by BioLineRx Ltd.

    3 - BioLineRx Ltd. (0001498403) (Issuer)

    3/18/26 5:26:21 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by BioLineRx Ltd.

    3 - BioLineRx Ltd. (0001498403) (Issuer)

    3/18/26 5:23:14 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    $ATXI
    $AURA
    $BLRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment

    -- European Commission decision anticipated in second quarter of 2026 -- BOSTON, March 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending to expand the current marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and the control of hunger in adults and children 4 years of age and above with acquired hypothalamic obesity (HO) due to hypotha

    3/26/26 9:01:56 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)

    GLIX1, a TET2 activator, is a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other cancers GLIX1 has demonstrated potent anti-tumor activity in multiple GBM models, excellent blood-brain barrier penetration and a favorable safety profile in preclinical toxicology studiesStudy is being conducted by world-leading glioblastoma investigators, led by Dr. Roger Stupp  TEL AVIV, Israel, March 26, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the initiation of a first-in-human, Phase 1/2a study of GLIX1 for th

    3/26/26 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioLineRx Reports 2025 Financial Results and Provides Corporate Update

    - On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month -- GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms -- Management to host conference call today, March 23, at 8:30 am EDT -TEL AVIV, Israel, March 23, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2025, and provided a corporate update. "Since our last quarterly update, we have been

    3/23/26 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    $ATXI
    $AURA
    $BLRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Durso Jerome Benedict bought $70,790 worth of shares (20,000 units at $3.54), increasing direct ownership by 160% to 32,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:00:05 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Wambeke David J. bought $670,400 worth of shares (1,000,000 units at $0.67) (SEC Form 4)

    4 - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Issuer)

    3/3/26 8:49:19 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    $ALT
    $ATXI
    $AURA
    $BLRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for APHEXDA issued to BIOLINERX, LTD.

    Submission status for BIOLINERX, LTD.'s drug APHEXDA (ORIG-1) with active ingredient MOTIXAFORTIDE has changed to 'Approval' on 09/08/2023. Application Category: NDA, Application Number: 217159, Application Classification: Type 1 - New Molecular Entity

    9/11/23 2:15:50 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    $ATXI
    $AURA
    $BLRX
    SEC Filings

    View All

    Amendment: SEC Form 20-F/A filed by BioLineRx Ltd.

    20-F/A - BioLineRx Ltd. (0001498403) (Filer)

    3/27/26 4:33:16 PM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Rhythm Pharmaceuticals Inc.

    SCHEDULE 13G/A - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    3/27/26 11:33:25 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Filer)

    3/26/26 4:06:16 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    $ATXI
    $AURA
    $BLRX
    Leadership Updates

    Live Leadership Updates

    View All

    Altimmune Announces CEO Transition and Succession Plan

    Jerry Durso, accomplished industry leader, to succeed Vipin Garg, Ph.D. as Chief Executive Officer Transition follows seven years of strong leadership by Dr. Garg GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and metabolic diseases, today announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company's President and Chief Executive Officer effective January 1, 2026. Altimmune's Chairman of the Board, Jerry Durso, will assume the role of President and Chief Executive Officer and retain his position as Chairman. To facilitat

    12/1/25 7:30:00 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward

    Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 ProgramThe ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class teamVIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026 ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platform compa

    11/20/25 8:00:00 PM ET
    $AURA
    $FDMT
    $NBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

    Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing c

    9/29/25 7:30:11 AM ET
    $ALT
    $XFOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ALT
    $ATXI
    $AURA
    $BLRX
    Financials

    Live finance-specific insights

    View All

    BioLineRx Reports 2025 Financial Results and Provides Corporate Update

    - On track to initiate Phase 1/2a clinical trial of GLIX1 for treatment of glioblastoma (GBM) by end of this month -- GLIX1 is positioned to potentially address unmet needs for novel and more effective cancer treatments by targeting DNA damage response mechanisms -- Management to host conference call today, March 23, at 8:30 am EDT -TEL AVIV, Israel, March 23, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2025, and provided a corporate update. "Since our last quarterly update, we have been

    3/23/26 7:00:00 AM ET
    $BLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

    -- First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction –  -- Indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity -- -- Approval based on -18.4% placebo-adjusted BMI reduction achieved by setmelanotide in global Phase 3 TRANSCEND trial [N=142] -- -- Company to host conference call today at 7:00 p.m. ET -- BOSTON, March 19, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceu

    3/19/26 6:30:00 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial

    -- Four substudies did not meet pre-specified primary endpoints --  -- Post hoc analyses show setmelanotide achieved statistically significant BMI reductions in patients with obesity due to a heterozygous variant of the POMC/PCSK1 and SRC1 (NCOA1) genes at 52 weeks – -- Conference call planned for 4:30 p.m. ET today – BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the topline results from its EMANATE trial. The four substudies of this global, Phase 3 trial evaluating setmelanotide did not meet

    3/16/26 4:01:00 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALT
    $ATXI
    $AURA
    $BLRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by NeuroOne Medical Technologies Corporation

    SC 13G/A - NEUROONE MEDICAL TECHNOLOGIES Corp (0001500198) (Subject)

    11/26/24 8:42:10 AM ET
    $NMTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Rhythm Pharmaceuticals Inc.

    SC 13G - RHYTHM PHARMACEUTICALS, INC. (0001649904) (Subject)

    11/14/24 9:50:26 PM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care